InterCure Regains Compliance with Nasdaq Minimum Bid Price Requirement

Nasdaq has closed its bid-price deficiency case against InterCure after the shares traded at or above $1.00 for 10 straight days.

Rhea-AI Summary

InterCure (INCR) has regained compliance with Nasdaq’s minimum bid price requirement as of September 8, 2026.

Nasdaq confirmed that for the 10 consecutive business days from August 24 through September 4, 2026, the closing bid price of InterCure’s ordinary shares was at or above $1.00 per share, satisfying Listing Rule 5450(a)(1). The company had previously been notified on February 25, 2026 that its bid price was below $1.00 for 30 consecutive business days and was given a 180-day grace period, until August 24, 2026, to regain compliance. After a September 1, 2026 delisting notice for not meeting the requirement within that period, Nasdaq has now determined the matter closed.

Positive

• Regained Nasdaq compliance: bid price at or above $1.00 for 10 consecutive business days through September 4, 2026
• Delisting threat removed: Nasdaq determined InterCure now meets Listing Rule 5450(a)(1) and closed the matter

Negative

• Prior non-compliance: shares traded below $1.00 for 30 consecutive business days, triggering a February 25, 2026 deficiency notice
• Delisting notice received: on September 1, 2026 Nasdaq stated the shares were subject to delisting after the 180-day grace period ended

Market Context

The August 19 reverse-share-split announcement coincided with a 5.48% decline; the current confirmat...

Analysis

The August 19 reverse-share-split announcement coincided with a 5.48% decline; the current confirmation showed that the earlier compliance effort reached its stated Nasdaq-listing objective.

Key Figures

Minimum bid price: $1.00 per share or greater Compliance period: 180 calendar days Prior bid-price deficiency: 30 consecutive business days +1 more

Minimum bid price

$1.00 per share or greater

Nasdaq compliance threshold

Compliance period

180 calendar days

Period provided to regain compliance

Prior bid-price deficiency

30 consecutive business days

Period below the Nasdaq minimum bid requirement

Qualifying bid-price period

10 consecutive business days

August 24 through September 4, 2026

Historical Context

1 past event · Latest: Aug 19

1 event

1. Aug 19

   Reverse share split

   24h Move

   -5.5%

   Reverse split aimed to raise share price and regain Nasdaq’s $1.00 minimum bid compliance.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

minimum bid price requirement, nasdaq listing rule 5450(a)(1), delisting, good manufacturing practices

4 terms

minimum bid price requirement regulatory

"regained compliance with the minimum bid price requirement"

A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.

nasdaq listing rule 5450(a)(1) regulatory

"set forth in Nasdaq Listing Rule 5450(a)(1)"

Nasdaq Listing Rule 5450(a)(1) is a continued-listing standard that sets a minimum share price companies must maintain to remain listed on the Nasdaq market—commonly a $1.00 per-share threshold. Investors care because falling below that floor can trigger a compliance review and possible delisting, which is like failing a minimum grade and losing access to the public market; delisting can reduce liquidity, visibility and the ability to raise capital.

delisting regulatory

"ordinary shares were subject to delisting"

Delisting occurs when a company's stock is removed from a stock exchange and is no longer available for trading there. This can happen voluntarily or because the company no longer meets the exchange's requirements. For investors, delisting means they can no longer buy or sell shares of that company on the exchange, which may make it more difficult to sell their investments or affect the stock's value.

View in glossary

good manufacturing practices technical

"Good Manufacturing Practices (GMP) certified"

Good manufacturing practices are a set of required processes, controls and documentation that ensure products are made consistently, safely and to quality standards — like following a precise recipe in a clean kitchen so every batch turns out the same. For investors, compliance matters because it affects a maker’s ability to get regulatory approval, avoid costly recalls or production stoppages, and maintain customer and market trust, all of which influence revenue and risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK and HERZLIYA, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (Nasdaq: INCR) (TASE: INCR) (“InterCure” or the “Company”) announced today that it received written confirmation from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The confirmation follows a written notification received by the Company from Nasdaq on September 1, 2026, indicating that the Company’s ordinary shares were subject to delisting from The Nasdaq Global Market (the “Delisting Notice”).

As previously disclosed, on February 25, 2026, the Company received notification from Nasdaq that the closing bid price of its ordinary shares had been below $1.00 per share for 30 consecutive business days and that the Company was therefore not in compliance with the Minimum Bid Price Requirement. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided a 180-calendar day compliance period, or until August 24, 2026, to regain compliance.

On September 1, 2026, the Company received the Delisting Notice stating that the Company had not regained compliance with the Minimum Bid Price Requirement within the applicable compliance period and that its ordinary shares were therefore subject to delisting from The Nasdaq Global Market. Subsequently, on September 8, 2026, Nasdaq notified the Company that, for the 10 consecutive business days from August 24, 2026 through September 4, 2026, the closing bid price of the Company’s ordinary shares was $1.00 per share or greater.

Accordingly, Nasdaq determined that the Company has regained compliance with Nasdaq Listing Rule 5450(a)(1), and that the matter is now closed.

About InterCure (dba Canndoc)

InterCure (dba Canndoc) (Nasdaq: INCR) (TASE: INCR) is the leading, profitable, and one of the fastest growing cannabis companies outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated “seed-to-sale” model to lead the fastest growing cannabis global market outside of North America.

For more information, visit: https://www.intercure.co 

Company Contact:

InterCure Ltd.
Amos Cohen, Chief Financial Officer
amos@intercure.co

FAQ

What Nasdaq rule did InterCure need to satisfy to regain compliance?

InterCure needed to satisfy Nasdaq Listing Rule 5450(a)(1), which requires a minimum bid price of $1.00 per share. Nasdaq later confirmed that this condition was met when the closing bid price was $1.00 or greater for 10 consecutive business days from August 24 through September 4, 2026.

How long was InterCure’s original grace period to fix the bid-price deficiency?

Under Nasdaq Listing Rule 5810(c)(3)(A), InterCure was granted a 180-calendar day compliance period, running until August 24, 2026, to regain compliance with the minimum bid price requirement after the February 25, 2026 notification.

What triggered Nasdaq’s initial bid-price deficiency notice to InterCure?

The initial notice was triggered when the closing bid price of InterCure’s ordinary shares was below $1.00 per share for 30 consecutive business days, as of the notification dated February 25, 2026.